Abstract Library

#2940 Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs)

Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rodriguez-Freixinos V

Authors: Rodriguez-Freixinos V, Chan D, Doherty M, Wasson K, Iscoe N,

Keywords: Poorly differentiated, G3 NECs, Avelumab, Immunotherapy,

#2793 A Phase II, Open-Label, Multicenter Trial of Avelumab in Patients with Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive after First-line Chemotherapy (AVENEC)

Introduction: High grade Neuroendocrine Neoplasias (NEN) are rare tumors with a poor prognosis and no established second line therapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Weber M

Authors: Fottner C, Apostolidis L, Ferrata M, Krug S, Michl P,

Keywords: NEC, NEN G3, check-point inhibitor, Avelumab, anti-PD-L1-antibody, immunotherapy,

#2248 High Grade (G3) Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Should the New WHO Classification Apply to All?

Introduction: Grade 3 (G3) neuroendocrine neoplasms (NEN), arising from the gastro-entero-pancreatic system (GEP), are classified according to WHO 2010 and defined as having a Ki67 of > 20%. However this groups together G3 well differentiated neuroendocrine tumours (WD-NET) with poorly differentiated neuroendocrine carcinomas (PD-NEC). Recently, WHO have proposed a new classification for pancreatic NEN, with sub-division into G3 WD-NET and G3 PD-NEC

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Furnace M

Authors: Furnace M, Muller G, Rundell C, Shah R, Luong T,

Keywords: G3, well-differentiated, poorly differentiated, Ki-67,

#2211 Clinicopathologic Characteristics of Chinese Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: Results of a Nation-Wide Retrospective Epidemiology Study

Introduction: he rare incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) has contributed to a paucity of large epidemiologic studies of patients with this condition, especially in China.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Yu P, Chi Y, Shi S, Chen Y, Jiang L,

Keywords: gastroenteropancreatic neuroendocrine neoplasms, clinicopathological characteristics, immunohistochemical staining,

#2079 Excellent Survival Outcomes for NET Patients Treated within NETwerk, a Collaborative ENETS Center of Excellence

Introduction: Since 2016, patients with neuroendocrine tumors (NETs) of 9 hospitals in Belgium, are jointly discussed during multidisciplinary tumor boards (NET MDT) within NETwerk, a ENETS Center of Excellence.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Vandamme T

Authors: Vandamme T, Maurissen I, Lybaert W, Simoens M, Abrams P,

Keywords: Neuroendocrine tumors, Care networking,